Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235468147> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4235468147 endingPage "183" @default.
- W4235468147 startingPage "165" @default.
- W4235468147 abstract "The quiet pandemic of herpes simplex virus (HSV) infection has plagued humanity since ancient times, causing mucocutaneous infection, such as herpes labialis and herpes genitalis. Disease symptoms often interfere with everyday activities and occasionally HSV infections are the cause of life-threatening or sight-impairing disease, especially in neonates and the immunocompromised patient population. After primary or initial infection the virus persists for life in a latent form in neurons of the host, periodically reactivating and often resulting in significant psychosocial distress for the patient. Currently, no cure is available. In the mid-1950s the first antiviral, idoxuridine, was developed for topical treatment of herpes disease and, in 1978, vidarabine was licensed for systemic use to treat HSV encephalitis. Acyclovir (Zovirax®), a potent, specific and tolerable nucleosidic inhibitor of the herpes DNA polymerase, was a milestone in the development of antiviral drugs in the late 1970s. In the mid-1990s, when acyclovir became a generic drug, valacyclovir (Valtrex®) and famciclovir (Famvir®), prodrugs of the gold standard and penciclovir (Denavir®, Vectavir®), a close analogue, were launched. Though numerous approaches and strategies were tested and considerable effort was expended in the search of the next generation of an antiherpetic therapy, it proved difficult to outperform acyclovir. Notable in this regard was the award of a Nobel Prize in 1988 for the elucidation of mechanistic principles which resulted in the development of new drugs such as acyclovir. Vaccines, interleukins, interferons, therapeutic proteins, antibodies, immunomodulators and small-molecule drugs with specific or nonspecific modes of action lacked either efficacy or the required safety profile to replace the nucleosidic drugs acyclovir, valacyclovir, penciclovir and famciclovir as the first choice of treatment. Recently though, new inhibitors of the HSV helicase-primase with potent in vitro antiherpes activity, novel mechanisms of action, low resistance rates and superior efficacy against HSV in animal models have been discovered. This review summarises the current therapeutic options, discusses the potential of preclinical or investigational drugs and provides an up-to-date interpretation of the challenge to establish novel treatments for herpes simplex disease." @default.
- W4235468147 created "2022-05-12" @default.
- W4235468147 creator A5038087675 @default.
- W4235468147 date "2003-01-01" @default.
- W4235468147 modified "2023-09-26" @default.
- W4235468147 title "Novel agents and strategies to treat herpes simplex virus infections" @default.
- W4235468147 doi "https://doi.org/10.1517/eoid.12.2.165.21401" @default.
- W4235468147 hasPublicationYear "2003" @default.
- W4235468147 type Work @default.
- W4235468147 citedByCount "2" @default.
- W4235468147 countsByYear W42354681472019 @default.
- W4235468147 crossrefType "journal-article" @default.
- W4235468147 hasAuthorship W4235468147A5038087675 @default.
- W4235468147 hasConcept C142724271 @default.
- W4235468147 hasConcept C159047783 @default.
- W4235468147 hasConcept C203014093 @default.
- W4235468147 hasConcept C2522874641 @default.
- W4235468147 hasConcept C2776409557 @default.
- W4235468147 hasConcept C2776543447 @default.
- W4235468147 hasConcept C2776723293 @default.
- W4235468147 hasConcept C2776724271 @default.
- W4235468147 hasConcept C2776824251 @default.
- W4235468147 hasConcept C2777333352 @default.
- W4235468147 hasConcept C2777374534 @default.
- W4235468147 hasConcept C2777965375 @default.
- W4235468147 hasConcept C2779134260 @default.
- W4235468147 hasConcept C2779756493 @default.
- W4235468147 hasConcept C2779820661 @default.
- W4235468147 hasConcept C2780452071 @default.
- W4235468147 hasConcept C2780727368 @default.
- W4235468147 hasConcept C2780796145 @default.
- W4235468147 hasConcept C2781088732 @default.
- W4235468147 hasConcept C2781196997 @default.
- W4235468147 hasConcept C2908647359 @default.
- W4235468147 hasConcept C55493867 @default.
- W4235468147 hasConcept C71924100 @default.
- W4235468147 hasConcept C86803240 @default.
- W4235468147 hasConcept C99454951 @default.
- W4235468147 hasConceptScore W4235468147C142724271 @default.
- W4235468147 hasConceptScore W4235468147C159047783 @default.
- W4235468147 hasConceptScore W4235468147C203014093 @default.
- W4235468147 hasConceptScore W4235468147C2522874641 @default.
- W4235468147 hasConceptScore W4235468147C2776409557 @default.
- W4235468147 hasConceptScore W4235468147C2776543447 @default.
- W4235468147 hasConceptScore W4235468147C2776723293 @default.
- W4235468147 hasConceptScore W4235468147C2776724271 @default.
- W4235468147 hasConceptScore W4235468147C2776824251 @default.
- W4235468147 hasConceptScore W4235468147C2777333352 @default.
- W4235468147 hasConceptScore W4235468147C2777374534 @default.
- W4235468147 hasConceptScore W4235468147C2777965375 @default.
- W4235468147 hasConceptScore W4235468147C2779134260 @default.
- W4235468147 hasConceptScore W4235468147C2779756493 @default.
- W4235468147 hasConceptScore W4235468147C2779820661 @default.
- W4235468147 hasConceptScore W4235468147C2780452071 @default.
- W4235468147 hasConceptScore W4235468147C2780727368 @default.
- W4235468147 hasConceptScore W4235468147C2780796145 @default.
- W4235468147 hasConceptScore W4235468147C2781088732 @default.
- W4235468147 hasConceptScore W4235468147C2781196997 @default.
- W4235468147 hasConceptScore W4235468147C2908647359 @default.
- W4235468147 hasConceptScore W4235468147C55493867 @default.
- W4235468147 hasConceptScore W4235468147C71924100 @default.
- W4235468147 hasConceptScore W4235468147C86803240 @default.
- W4235468147 hasConceptScore W4235468147C99454951 @default.
- W4235468147 hasIssue "2" @default.
- W4235468147 hasLocation W42354681471 @default.
- W4235468147 hasOpenAccess W4235468147 @default.
- W4235468147 hasPrimaryLocation W42354681471 @default.
- W4235468147 hasRelatedWork W2015235814 @default.
- W4235468147 hasRelatedWork W2027210619 @default.
- W4235468147 hasRelatedWork W2087950464 @default.
- W4235468147 hasRelatedWork W2114542224 @default.
- W4235468147 hasRelatedWork W2164698685 @default.
- W4235468147 hasRelatedWork W2300034093 @default.
- W4235468147 hasRelatedWork W2463877815 @default.
- W4235468147 hasRelatedWork W3162141124 @default.
- W4235468147 hasRelatedWork W4214814700 @default.
- W4235468147 hasRelatedWork W4253747120 @default.
- W4235468147 hasVolume "12" @default.
- W4235468147 isParatext "false" @default.
- W4235468147 isRetracted "false" @default.
- W4235468147 workType "article" @default.